• Dr Emilie Alirol, Coordinator, MAS in Drug Development and DAS in Management of Clinical Trials, Clinical Trial Unit (CTU), University Hospitals of Geneva, Geneva (CH)
  • Dr Emilie Alirol

    Coordinator, MAS in Drug Development and DAS in Management of Clinical Trials, Clinical Trial Unit (CTU), University Hospitals of Geneva, Geneva (CH)

    Emilie Alirol obtained her PhD in molecular biology from the University of Geneva in 2006. She has over 12 years experience in biomedical research, including 8 years in managing and coordinating multinational clinical trials in Switzerland and low/middle income countries. Emilie Alirol spent 5 year as a Clinical Research Associate (CRA) in the Clinical Trials Unit of Geneva University Hospitals, focusing on infectious diseases, and coordinating phase 2 to 4 trials. She has been involved in both therapeutic and diagnostic trials. In 2013 she moved to Médecins Sans Frontières (MSF) where she was the Clinical Trial Manager of an MSF-sponsored trial on Multi-Drug Resistant Tuberculosis (MDR-TB). Emilie Alirol has been an Ethics Committee member since 2010 and she is currently the vice chair of the WHO Research Ethics Review Committee. Since 2011 she has also been engaged in training and education on clinical trials. She sat up the Diploma of Advances Studies (DAS) in Management of Clinical Trials with the University of Geneva in 2011 and since January 2016 she has been tasked with the set up of the new MAS in Drug Discovery and Clinical Development.

  • Dr Manica Balasegaram, Director, Global Antibiotic R&D Partnership (GARD) @DNDi
  • Dr Manica Balasegaram

    Director, Global Antibiotic R&D Partnership (GARD) @DNDi

    Manica Balasegaram has a background in internal/emergency medicine, having earned his bachelor of medicine/bachelor of surgery degree from Nottingham University Medical School in the UK in 1996. He also has a master’s degree in Public Health in Developing Countries and a diploma in Tropical Medicine from the London School of Hygiene and Tropical Medicine. Prior to becoming Director of the Access Campaign in August 2012, he was Head of the Leishmaniasis Clinical Development Programme in DNDi (Drugs for Neglected Diseases initiative) where he was responsible for numerous clinical trials and development projects, particularly in Africa and South Asia. He has also been Head of the Manson Unit, a medical research and implementation unit of Médecins Sans Frontières (MSF) and has worked in the field in Uganda, Sudan, the Republic of Congo, Ethiopia, India, and Bangladesh. Manica Balasegaram has extensive clinical experience in tropical medicine, including malaria, sleeping sickness, and visceral leishmaniasis. He has also been involved in research and several clinical trials on malaria, sleeping sickness and leishmaniasis, where he was worked in several positions ranging for site and principal investigator to project manager and a portfolio development leader. In his role as Director of the Access Campaign, he was responsible for working on issues related to access to new and adapted technologies- especially drugs, diagnostics and vaccines with a focus on TB, HIV, Neglected Diseases and Vaccines. In June 2016, Manica Balasegaram was appointed Director of the Global Antibiotic Research & Development (GARD) partnership, a joint WHO/DNDi initiative incubated by DNDi in support of the Global Action Plan for Antimicrobial Resistance.

  • Dr Roch Ogier, Chief Scientific Officer, Novartis Pharma Schweiz AG, Rotkreuz (CH)
  • Dr Roch Ogier

    Chief Scientific Officer, Novartis Pharma Schweiz AG, Rotkreuz (CH)

    Roch Ogier is a medical doctor and holds a PhD in Neurosciences from the University of Geneva, which he obtained in 2006. He completed his curriculum with advanced studies in Healthcare Management (HEC, Geneva), Pharmaceutical Medicine (ECPM, Basel), Leadership (GCU, UK) and eHealth (IKF, Luzern). After several years in academia (basic and clinical research, medical education), Roch Ogier joined the pharmaceutical industry in 2007 with medical leadership roles at Sanofi-Aventis and Vifor Pharma in Switzerland. Since 2013 he is Chief Scientific Officer at Novartis, where he is responsible for clinical research, drug safety and medical affairs for Switzerland. He is also co-founder of Firstmed SA, a company that provides training and services in the field of first aid.

  • Dr Francois Curtin, Chief Operating Officer, GeNeuro SA, Geneva (CH)
  • Dr Francois Curtin

    Chief Operating Officer, GeNeuro SA, Geneva (CH)

    François Curtin graduated from the University of Geneva in 1989 with an MD and from the University of London in 1999 with a Master of Philosophy in Medical Statistics. After several years in academic clinical research, he joined Swissmedic in 2001 where he was responsible for the registration and market surveillance of the neuropsychiatric drugs. In 2003, François joined Serono SA and worked in different management positions in clinical and business development, with a particular focus on neurology and monoclonal antibodies. François has been the Chief Executive Officer of GeNeuro SA from 2009 to 2016, a biotech company active in the development of monoclonal antibodies to treat neuro-inflammatory disorders. François is a Privat Docent at the Faculty of Medicine of the University of Geneva since 2003 and an Academic Fellow of the Geneva School of Economics and Management, co-responsible of the Biostatistics module.

  • Dr Catherine Deloche, COO, Solid drug development SA, Geneva (CH)
  • Dr Catherine Deloche

    COO, Solid drug development SA, Geneva (CH)

    Catherine Deloche is a Pharmacist by training (Pharm. D obtained in 1990), and holds a certificate in Clinical Pharmacy (obtained in 1991 from the University of Lyon I) and a Ph.D. in Clinical Pharmacology from the University of Geneva (1997). Catherine Deloche has twenty years of experience in non-clinical and clinical aspects of drug development with in-depth experience of European and US Drug Regulations acquired both in a European pharmaceuticals development consultancy, Triskel Integrated Services (1997-2008) and a Biotech Company, Ribovax (2008-2010). Under her leadership, Solid drug development SA is currently developing therapeutic products from bench up to their final registration.

  • Dr Patricia Delaite, Medical Director, Incyte, Geneva (CH)
  • Dr Patricia Delaite

    Medical Director, Incyte, Geneva (CH)

    Patricia Delaite graduated from the University of Geneva with an MD and from the Lausanne Business School/EPFL with a Master in Business Administration focusing on Life Sciences management. After ten years spent in academic clinical care management while obtaining her specialization in Internal Medicine and in Oncology, she joined the biopharmaceutical industry and held various positions in Clinical development, at local, regional and global level. In her current role, she is leading the design and oversight of two drug development programs with a particular focus on shaping the host micro-environment and targeting a worldwide launch. She is also actively involved in elaborating company specific drug development guidance and in building capabilities/collaborative partnership with HAs, HTAs and External Partners.

  • Prof. Michel Lièvre, Retired associate professor of pharmacology, Lyon Est Faculty of Medicine, Claude Bernard University, Lyon (France)
  • Prof. Michel Lièvre

    Retired associate professor of pharmacology, Lyon Est Faculty of Medicine, Claude Bernard University, Lyon (France)

    Michel Lièvre was trained as a veterinary doctor and holds a PhD in human biology (pharmacology) and a diploma in clinical toxicology. He has been involved in clinical research for many years, as a coordinator, but also as a member of clinical trials and observational studies steering committees. Michel Lievre has also been and is a member and chairman of several Data Safety Monitoring Boards (DSMB). He has worked for more than 20 years for the French drug agency (AFSSAPS and ANSM) in several commissions, and for the French Haute Autorité de Santé. He teaches pharmacology, methods in clinical trials, critical assessment of clinical trials and pharmaco-epidemiologic studies, as well as ethics in biomedical research.

  • Dr Christine Maure, Project manager, Global Vaccine Safety Group, Department of Essential Medicines and health products, World Health Organization (WHO), Geneva (CH)
  • Dr Christine Maure

    Project manager, Global Vaccine Safety Group, Department of Essential Medicines and health products, World Health Organization (WHO), Geneva (CH)

    Christine Maure is Pharm D by education and obtained her degree from the University of Rouen, France in 1995. She specialized in clinical research and public health, and in 2012 obtained a Master of International Public Health from the Institut de Santé Publique, d’Epidemiologie et de Développement, Bordeaux (France). Christine Maure’s career spans both the public and private sectors. She has spent the first 10 years of her career in the pharmaceutical industry (GSK and Servier) where she was in charge of the clinical development of new drugs for non-communicable diseases. She then moved to the public sector, joining the Special Programme for research and training in tropical diseases (TDR) of the WHO in 2007. In TDR she implemented a Quality Management System for health research activities, and promoted good research practices and bioethics in developing countries, through the organization of short courses for researchers, ethics review committee members and regulators. Christine Maure progressively expanded her scope of activities, developing and managing various capacity building programmes aiming to strengthen individual and institutional health research capacities in low and middle income countries. She is now supporting countries in strengthening their capacities in vaccine pharmacovigilance system.

  • Dr Corinne Merle, Scientist, Intervention and Implementation research unit, Special Programme for research and training in tropical diseases (TDR), World Health Organization (WHO), Geneva (CH)
  • Dr Corinne Merle

    Scientist, Intervention and Implementation research unit, Special Programme for research and training in tropical diseases (TDR), World Health Organization (WHO), Geneva (CH)

    Corinne Merle has a medical background (MD, 1996, Reims University, France) with a specialization in infectious diseases (DESC of Tropical and Infectious Diseases) and in Public Health (DES of Public Health & Epidemiology, Reims University, France / BSc of Statistics, Kremlin Bicetre, France / MSc of Epidemiology and Statistics, Nancy, France / MSc of Economic and Policy of Health, Paris Sorbonne, France). Her main research areas are TB and HIV. She has been working in the field of clinical trials for almost 20 years and has been involved in various types of trials, from phase II, phase III, to PK/PD studies. She spent 10 years at the London School of Hygiene and Tropical Medicine where, among other academics ‘duties, she was coordinating a phase III randomized controlled trial recruiting patients from 5 countries in Africa (OFLOTUB project) and another phase III trial assessing in West Africa 3 strategies of treatment for TB/HIV co-infected patients (RAFA project). Since October 2014, she joined the Special Programme for research and training in tropical diseases (TDR) of WHO.

  • Prof. Philippe Ducor, Professor, Faculty of Law, University of Geneva, Geneva (CH)
  • Prof. Philippe Ducor

    Professor, Faculty of Law, University of Geneva, Geneva (CH)

    Philippe Ducor is a professor at the University of Geneva Law School and the director of the Master in Life Sciences Law program, where he teaches technology transfer and biotechnology law. He also practices law at a Geneva business law firm. Philippe is fully trained in medicine and law (both at PhD level, including professional medical and legal certifications) and obtained degrees from the Universities of Geneva and Stanford. His areas of expertise cover pharmaceutical and biotechnology law, health law, medical malpractice, intellectual property and unfair competition. His work has been published in legal and scientific journals, such as Nature and Science.

  • Dr Hervé Porchet, Chief Medical Officer (CMO), Geneuro, Geneva (CH)
  • Dr Hervé Porchet

    Chief Medical Officer (CMO), Geneuro, Geneva (CH)

    Hervé Porchet graduated with an MD from the University of Lausanne. After working 12 years in University Hospitals (Bern, Geneva and San Francisco), he obtained three Medical Specialist Degrees, in Internal Medicine, Clinical Pharmacology and Toxicology, and Pharmaceutical Medicine. Hervé Porchet has an extensive experience in clinical, as well as pre-clinical drug development, in numerous therapeutics areas. He gained this experience by working as a clinical pharmacologist at the interface of pre-clinical and clinical development for more than 25 years (Ares-Serono Corporate Director Clinical Pharmacology 1991 - 1995, Debiopharm VP Medical Affairs 1995 – 1997 and 1998 - 2011, Triskel Services CMO 1997 - 1998, Eclosion CMO 2011 - 2012, GeNeuro CMO since 2012, Pharmana Consulting President since 2012). He fully implemented and managed the registration of three US NDAs, three Canadian NDSs, and three EU Mutual Recognition Procedures (MRP) and one Decentralized Procedure. Since 2014, Hervé Porchet is also Extraordinary Professor of Pharmacology at the University of Pretoria, South Africa.

  • Dr Jocelyne Chabert, Clinical Research Associate (CRA), Clinical Trials Unit (CTU), University Hospitals of Geneva (HUG), Geneva
  • Dr Jocelyne Chabert

    Clinical Research Associate (CRA), Clinical Trials Unit (CTU), University Hospitals of Geneva (HUG), Geneva

    After a PhD in biological and medical engineering, Jocelyne Chabert directed her career towards clinical research. Holder of an interuniversity French diploma (clinical trials training for investigators –FIEC University of Lyon I), she began her career as a CRA by joining the Division of Clinical Pharmacology and Toxicology in 2002. There, she actively participated in numerous clinical trials (phases I to III) from the investigator side, and she naturally joined the Geneva Clinical Trial Unit (CTU) when it was created in 2008. Jocelyne Chabert is now involved in the quality assurance activities of the CTU and is responsible for the oversight of all monitoring activities of the CTU. She also provides support to investigators from the University Hospitals of Geneva on regulatory aspects of clinical trials and on communications with the Swiss regulatory authorities. Jocelyne Chabert is also involved in various training and set up the e-learning "Good Clinical Practices training for sub-investigators” (http://gcp.hug-ge.ch/).

  • Dr Vanya Beltrami, Vice-President, Head of Manufacturing, Anergis, Epalinges (CH)
  • Dr Vanya Beltrami

    Vice-President, Head of Manufacturing, Anergis, Epalinges (CH)

    Vanya Beltrami was trained as a pharmacist and holds a PhD in formulation which he obtained from the University of Geneva in 1990. He started his career as a Medical Research Associated with Ares-Serono in 1990. Between 1991 and 2013, he held several positions with increasing responsibilities in drug development within Laboratoires Serono SA and then Merck Serono SA. In the last years, he became a Global Product Team Leader at Merck Serono Head Quarter in Geneva, expanding substantially his cross-functional pharmaceutical development experience. Vanya Beltrami was involved in the development, registration and launch of several injectable formulations or devices for Merck Serono brand growth hormone (e.g. Saizen®, Serostim®, Cool.Click®, Easypod®) in multiple countries worldwide. After a short period of consultancy he joined Anergis in May 2014 as Director Product Development and since July 2015 he is acting as Vice-President, Head of Manufacturing. He is currently in charge of the development of both drug substances and drug products, including the related analytical methods, in collaboration with external contract manufacturing organizations.